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Abstract While various clinical applications especially in on-
cology are now in progress such as diagnosis, prognosis, ther-
apy monitoring, or patient follow-up, the determination of
structural characteristics of cell-free circulating DNA
(cirDNA) are still being researched. Nevertheless, some specif-
ic structures have been identified and cirDNA has been shown
to be composed of many Bkinds.^ This structural description
goes hand-in-hand with the mechanisms of its origins such as
apoptosis, necrosis, active release, phagocytosis, and exocyto-
se. There are multiple structural forms of cirDNA depending
upon the mechanism of release: particulate structures
(exosomes, microparticles, apoptotic bodies) or macromolecu-
lar structures (nucleosomes, virtosomes/proteolipidonucleic ac-
id complexes, DNA traps, links with serum proteins or to the
cell-free membrane parts). In addition, cirDNA concerns both
nuclear and/or mitochondrial DNAwith both species exhibiting
different structural characteristics that potentially reveal differ-
ent forms of biological stability or diagnostic significance. This
review focuses on the origins, structures and functional aspects
that are paradoxically less well described in the literature while
numerous reviews are directed to the clinical application of
cirDNA. Differentiation of the various structures and better
knowledge of the fate of cirDNA would considerably expand
the diagnostic power of cirDNA analysis especially with regard
to the patient follow-up enlarging the scope of personalized
medicine. A better understanding of the subsequent fate of
cirDNA would also help in deciphering its functional aspects
such as their capacity for either genometastasis or their pro-
inflammatory and immunological effects.
Keywords Cell-free circulating DNA . Cancer . Structures .
Origins . Functions
1 The origin of the cirDNA concept
1.1 Extracellular DNA
The term extracellular DNA concerns both nuclear and/or
mitochondrial DNA liberated from the cell. They are found
in the physiological extracellular milieu, e.g., blood, lymph,
bile, milk, urine, saliva, mucous suspension, spinal fluid, and
amniotic fluid. These extracellular DNA molecules are found
in humans and both the animal and plant kingdoms. In addi-
tion, extracellular DNA molecules are found and released in
cell culture supernatants either from cell lines, primary cells,
organoids, or embryo cultures [1].
1.2 Extracellular circulating DNA
This term is reserved for extracellular DNA molecules found
in the physiological circulating fluids (see Sect. 1.1). In the
following work, these extracellular circulating nucleic acids
will be designated by the term circulating DNA (cirDNA). We
are specifically interested in the circulating DNA present in
the blood.
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1.3 History
Researchers in the 1940s and 1950s were very much geared to
the determination of the chemical nature of the gene leading to
the identification of DNA as the principle component and to
the gene-DNA theory in 1957 (Table 1). As a consequence,
the first demonstration of DNA and RNA in the blood of
healthy individuals and diseased patients by Mendel and
Métais in 1948 [8] was ignored (Fig. 1). Subsequent to their
discovery, Tan et al., as late as 1966, showed that circulating
DNAwas present in the blood of systemic lupus erythemato-
sus (SLE) patients leading to the formation of anti-dsDNA
antibodies [27]. In the field of oncology, Leon et al. revealed,
in 1977, that the concentration of cirDNA from cancer patients
is greater than that from healthy individuals, opening the way
to potential biomedical applications in oncology [21].
However, it was not until 1989 that cirDNA was recognized
whenMaurice Stroun and Philippe Anker showed that in can-
cer patients, cirDNA was, in part, of tumoral origin since it
harbored the particular double-strand instability specific to
tumor DNA [22]. In 1994, Vasioukhin et al. and Sorenson et
al., in collaboration with P. Anker, found that cirDNA bore
RAS point mutations specifically found in tumor cells [23, 24].
Since then, the concept of a Bliquid biopsy^ was born. In
parallel, cirDNA had become of interest in another clinical
domain: in 1997, Lo et al. showed that DNA of fetal origin
circulated in the blood of pregnant women [25], permitting the
early identification of fetal genetic anomalies, such as Down
syndrome [28], through a simple maternal blood sample and
to avoid amniocentesis and other invasive techniques that pre-
sented risks and complications. Analysis of fetal cirDNA from
maternal blood collection additionally affords both sex and
Rhesus factor determination [29, 30]. Concerning the field
of medically assisted procreation, extracellular DNA analysis
is promising: at the moment, pre-implantation diagnosis is
made by aspiration of one or two cells from the embryo, im-
posing traumatic risks and consequences for the implantation
of the embryos [31]. Extracellular DNA analysis from the
embryonic culture medium will permit avoidance of these
complications and yield genetic information by DNA se-
quence analysis and quality by its structure. Publication fre-
quency for the past 50 years shows the increased interest by
the community concerning cirDNA. Promising other potential
clinical applications from cirDNA analysis were shown, such
Table 1 Timeline for discoveries on cirDNA
Timeline discoveries on circulating cell-free DNA
Date Authors Discovery
1871 Miescher DNA isolation (nucleine) [3]
1929 Levene, Haller Identification of first particular structures of DNA [4]
1941 Beadle, Tatum One gene - one enzyme [5]
1944 McCLintock Jumping genes [6]
1944 Avery et al. DNA carrier of genetic information [7]
1948 Mandel, Métais Circulating nucleic acids in human blood [8]
1949 Chayen, Norris Cytoplasmic localization of DNA [9]
1950 Swift DNA constancy [10]
1950 Chargaff Base parity rule [11]
1953 Watson, Crick Identification of DNA structure [12]
1953 Wilkins et al. Identification of DNA structure [13]
1957 Sinsheimer Gene concept [14]
1959 Gartler DNA uptake by cells [15]
1962 Gahan, Stroun DNA mobility [16, 17]
1965 Gahan, Chayen Messenger DNA [18]
1972 Stroun, Anker Active secretion of DNA by cells [19]
1977 Stroun et al. Characterization and definition of cirDNA [20]
1977 Leon et al. Higher cirDNA concentrations in cancer patients [21]
1989 Stroun et al. Identification of tumor-derived cirDNA [22]
1994 Anker et al. RAS mutation detection by cirDNA analysis [23, 24]
1997 Lo et al. Identification of fetal derived cirDNA [25]
2005 Diehl et al. Large cohorts of patients for screening of point mutations
by cirDNA analysis [26]
Adapted from Gahan and Swaminathan [2]
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as for autoimmune diseases (SLE), inflammatory diseases
(rheumatoid arthritis, Crohn’s disease), systemic disorders
(granulomatosis with polyangiitis), trauma, sepsis, or myocar-
dial infarction [32]. Since 2005, many clinical studies have
been performed implicating a role for cirDNA; however, such
analyses are still to be validated in clinical practice [32–35].
Table 1 provides a timeline of the main discoveries concerning
cirDNA prior to the concept of Bliquid biopsy^ in oncology as
well as those concerning the structural and functional aspects
of cirDNA.
A high proportion of the investigations on cirDNA directed to
clinical relevance are in the field of oncology. The results
obtained for many different cancers have opened a new research
area indicating that plasma DNA might eventually be a suitable
target for the development of non-invasive diagnostic, prognos-
tic, treatment monitoring and follow-up tests for cancer [35].
2 Biological aspects of cirDNA
2.1 Origins
The determination of structural characteristics of cirDNA is
still under investigation. Nevertheless, some structures have
Fig. 1 The first identification of extracellular nucleic acids in human blood compartment by Mandel and Metais in 1948 (adapted from Mandel and
Métais [8])
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been identified and cirDNA has been shown to be composed
of many Bkinds^. This structural description goes hand-in-
hand with the mechanisms of its origins; in effect, the
cirDNA structures can be envisaged as signatures of the re-
leasing mechanisms. While this research has progressed at the
rhythm of discoveries concerning cirDNA, the technological
revolution has permitted an increased sensitivity in the identi-
fication of these structures. The following section reconsiders
the major discoveries since the 1960s.
2.1.1 General characteristics of circulating DNA
Since 1966, work on auto-immune pathologies has permitted
the first characterization of cirDNA [27, 36–45]. These studies
were based upon the constant finding that in SLE, dsDNA
antibodies are found in the blood circulatory compartment.
The hypothesis that the DNA could be found directly in the
circulatory system complexed with the dsDNA antibodies was
demonstrated and confirmed. Tan et al. were the first to show
the presence of DNA in the human circulatory system of SLE
patients [27]. This first discovery initiated a number of re-
search studies in this area, leading to the first structural obser-
vations concerning cirDNA. Subsequently, the presence of a
complex structure was shown to be composed of a variety of
types of DNA of different sizes [45]. Some workers showed
single-stranded fragments [38] while others showed double-
stranded fragments [27].
With regard to cancer, Stroun et al., in 1987, isolated and
characterized cirDNA found in cancer patients [46]. After dis-
sociation of the original nucleoprotein complex, these authors
showed that at that moment, the cirDNAwas double-stranded
and measured 0.5–21 kbp, revealing that cirDNA of cancer
origin is smaller than genomic DNA. Since then, it is consid-
ered that cirDNA is made up of DNA fragments. Two years
later, Stroun et al. identified specific properties of the cirDNA
of cancer origin showing that the double-stranded DNA of
tumor origin is less stable than that derived from non-tumour
cells [22]. Advanced technologies, as well as data resulting
from investigation of the release mechanisms, enabled further
understanding of the cirDNA characteristics and origins.
2.1.2 A more precise structural identification: Bsignature^
of the release mechanism
DNA is a very electrostatic molecule with properties of auto-
condensation and an ability to complex with other molecules or
structures [47]. It has been shown that cirDNA is present either
in molecular or macromolecular complexes or internalized in
vesicles [48, 49] (Fig. 2). Such structures protect it from nucle-
ases present in the circulatory system and reduce recognition as a
danger signal by the immune system [50]. cirDNA can equally
be attached to the exterior of the cell membrane from which it
can be detached and so be freed in the circulatory system [48,
49]. Different mechanisms can be envisaged that permit the
translocation of DNA from the intracellular to the extracellular
compartment yet remaining biologically stable. The structural
description of cirDNA is reflected in its origins: apoptosis,
necrosis, phagocytosis, oncosis, and active secretion have all
been evoked and linked to particular structures. The mechanism
of active secretion was demonstrated by M. Stroun, P.
Gahan, and P. Anker leading to the discovery of the virtosome
[51, 52]. Their studies on non-dividing cells such as lympho-
cytes and frog heart auricles have shown a nucleoprotein com-
plex that was synthesized and spontaneously secreted through a
regulated mechanism [19, 53–62]. Abolhassani et al. have
equally shown an active secretion of extracellular DNA from
the HL60 cell line [63]. Moreover, it has been found that frag-
ments of cirDNA found in cancer patients contained the
hTERT and hTr sequences that are not found in the genetic
material of apoptotic cells [61].
2.1.3 Cellular origins of tumor cirDNA
General considerations The rate of solid tumour progression is
a long process of some 10 years. Three parameters affect tumor
growth kinetics: these concern tumor doubling time, the tumor
proliferation coefficient, i.e., the number of proliferating cells,
and lastly, the level of tumor cell loss factor [64]. Concerning
colorectal cancer, theoretical data indicate that the tumor dou-
bling time is 90 days, the cell loss factor is of 96%, and the level
of cell proliferation is 15% [65]. The doubling time and the level
of cell loss are particularly high, explaining both the long time
for the appearance of this cancer and its Gompertzian growth
[66]. The cell loss factor of 96% is particularly interesting for our
work: these cell losses are due to the phenomenon of cell death
and indicates that this tumor could be at the origin of a massive
liberation of DNA into the extracellular compartment.
Bettegowda et al. reported a high variation of the cirDNA
Fig. 2 Potential vesicular structures of circulating DNA (from Rykova et
al. [48])
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amount in blood of patients depending upon the types of cancer
with bladder, colorectal, ovarian, pancreas, and breast cancer
exhibiting more than fivefold and tenfold amounts as compared
to thyroid and glioma cancer, respectively [67]. Over and above
the mechanisms at the origin of DNA release into the blood-
stream, it is necessary to consider the cellular origins of the
DNA found in the blood of cancer patients. The identification
of genetic alterations in cirDNA specific to cancer cells has
permitted the demonstration that the tumor cell compartment
was a source of cirDNA. Nevertheless, the basal amount of
cirDNA found in healthy individuals indicates that other non-
tumour cells constitute a source of DNA release. In addition, a
tumor is composed of malignant tumor cells, but equally of an
ensemble of cells constituting the tumor microenvironment.
Thus, stromal cells, endothelial cells, lymphocytes, and other
immune cells equally constitute a potential source of cirDNA
release in relation to tumor progression [47].





Each of these compartments may be subjected to different
processes generating the release of different forms of DNA
into the circulatory system. Figure 3 gives a resume of the
cellular sources and mechanisms of release of cirDNA found
in cancer patients.
Tumor cell origin of cirDNA It has been demonstrated that
the amount of cirDNA in the circulation compartment increases
with tumor cell number increase. More elevated amounts are
found in blood from advanced and metastatic cancer patients
[67–71] than in early stage cancer patients. Higher levels of
cirDNA (5–1500 ng/mL) found in cancer patients as compared
to healthy individuals (1–5 ng/mL) [69, 72] result from the
release of cirDNA both by malignant and non-malignant cells
since the germline cirDNA level deriving from normal cells
stays constant [47, 68, 73]. Therefore, elevated cirDNA levels
may account for the tumor burden [68, 73, 74] (Fig. 4). It is
reasonable to postulate that the total mutant cirDNA concen-
tration accounts for the cirDNA deriving from malignant cells
[74]. Thus, examination of the mutational load or the propor-
tion of the mutant cirDNAwithin the total amount of cirDNA,
first observed by Mouliere et al. [68–70, 74] and subsequently
in various studies [67, 75], demonstrated that their respective
amount varies greatly (from 0.003 to 95 %), highlighting a
strong interindividual heterogeneity (Fig. 5). Moreover, in our
studies, one third of the mutant plasma samples may exhibit a
mutation load higher than 25 % [69, 70].
Hence, we suggest that either tumor cells variably release
DNA as compared with the tumor surrounding stroma cells
and normal cells or that mutant DNA analysis may depend
upon tumor clonality. The detection of point mutation by
quantifying the proportion of mutant circulating tumor DNA
as presented here provides a powerful means toward assessing
the proportion of cirDNA from different origins [47].
In spite of the numerous studies examining only circulating
tumor-derived DNA, the total cirDNA concentration in the
circulation compartment should be assessed since it better
corresponds to the tumor mass especially when the total
cirDNA concentration is high (i.e., > 20 ng/mL). It should
be associated with the circulating tumor DNA level to better
Fig. 3 Distinct cellular origins of
circulating DNA found in the
blood of cancer patients
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understand the tumor dynamics and the clonal heterogeneity
over time and seems a valuable biomarker for tumor burden or
tumor progression.
This is of particular importance when considering that a
low proportion of malignant cells in colorectal cancer is relat-
ed to poor cancer-specific survival [76]. In 2012, Spindler et
al. showed the prognostic value of the total cirDNA concen-
tration and mutant cirDNA concentration for a cohort of met-
astatic colorectal cancer patients [77]. Furthermore, our stud-
ies on metastatic colorectal cancer showed that high levels of
total cirDNA and mutant cirDNA were strongly correlated
with diminution of overall survival as well as high levels of
mutation load (mutant allele frequency) and high cirDNA
fragmentation level [74] (Fig. 6). An investigation toward
Fig. 4 Circulating DNA levels correlate with tumor burden. a SW620
xenografted mouse model. Quantification by Q-PCR of cirDNA derived
from malignant and non-malignant cells in the mouse model. Tumor
weight is represented by the red curve (right axis). Concentration of
cirDNA derived from mouse (normal) cells (mWT cirDNA) in control
(not grafted) mice (mouse nos. 1–3) and in athymic nude mice (mouse
nos. 4–11) xenografted with the SW620 colorectal human cells, deter-
mined using a primer set targeting a mouse KRAS second intron WT
sequence. b SW620 xenografted mouse model. Concentration of
cirDNA derived from human cells (hWT cirDNA) using a primer set
targeting a human KRAS second intron WT sequence. c SW620
xenografted mousemodel. Concentration of cirDNAderived from human
cells (hKRASm cirDNA) using a primer set targeting a human KRAS
second exon sequence that contains the G12V point mutation present in
SW620. d Clinical mCRC plasma samples. Correlation between total
cirDNA level andmutant cirDNA level in 4KRASmutant mCRCpatients
(adapted from Mouliere et al [68] and El Messaoudi et al. [74]) (color
figure online)
Fig. 5 Strong interindividual heterogeneity of cirDNA mutation load
values (mutant allele frequencies) (adapted from Mouliere et al. [68])
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deciphering the role of the tumor environment cells in other
endothelial cancers or other cancer types and in primary ver-
sus metastatic tumor tissue would benefit from distinguishing
between the concentration of mutant and non-mutant cirDNA.
This former observation might account for the role of autoph-
agy and hypoxia on cirDNA release either in respect to their
structural forms or amount released in the blood stream [78].
Both physiological conditions are linked to the tumor micro-
environment. Autophagy is associated with citrullination of
histones to allow for the unwinding and subsequent expulsion
of DNA. Autophagy also ensures the physiological turnover
of old and damaged organelles being an adaptive response
under stressful conditions. As such, autophagic activity regu-
lates apoptosis and, as a consequence, cirDNA release.
Hypoxia is proposed as a major process involved in tumor
growth, invasion, and metastasis [79]. Malignant cells could
activate autophagy as a survival mechanism, allowing an al-
ternative energy source from their self-digestion. Conversely,
Sato et al. revealed that while autophagy was activated in
malignant cells, it was not activated in cells from the micro-
environment [80]. This phenomenon could explain the high
level of specific malignant-derived cirDNA observed in some
Fig. 6 Correlation of circulating DNA parameters and overall survival.
Overall survival analysis on a set of mCRC patients with KRAS or BRAF
mutation. a Kaplan-Meier survival curve and log-rank test according to
mA (mutant cirDNA concentration) determined by cirDNA analysis di-
chotomized around the median (3.06 ng/mL, n = 43). b Kaplan-Meier
survival curve and log-rank test according to mA% (mutation load) di-
chotomized to the first tertile (4.14 %) determined by cirDNA analysis
(n = 43). c Kaplan-Meier survival curve and log-rank test according to
Ref A KRAS (total cirDNA concentration) dichotomized around the
second tertile (107.0 ng/mL, n = 43). d Kaplan-Meier survival curve
and log-rank test according to DNA integrity index (DII) determined by
cirDNA analysis dichotomized around the second tertile (0.20, n = 43)
(from El Messaoudi et al [74])
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cases. CirDNA release was found to be clearly dependent
upon hypoxic conditions [79] and could be of diagnostic in-
terest for solid tumors especially for tumors with an extreme
hypoxic signature such as pancreatic cancer, and so could be
proposed as a marker for the screening or surveillance for
pancreatic cancer [81].
Mitochondrial-derived cirDNA In addition, mitochondrial-
derived cirDNA (cirmtDNA) has been found in the blood of
healthy subjects and patients with various diseases, especially
in cancer patients [82]. Important levels of cirmtDNA copies
have been found in the blood of both cancer patients [83, 84]
and healthy individuals [85]. Mitochondrial DNA is released
in the circulation following general mechanisms of cell death
and specific mitophagy cell death [86]. Their circulating struc-
tures are poorly known: however, it seems that they are pres-
ent as either bound to internal and external mitochondrial
membrane fragments or as intact cell-free mitochondrial
DNA [87]. Nevertheless, analysis of cirmtDNA appears now
to be of great importance with numerous studies showing
diagnostic applications in various diseases (e.g., diabetes,
acute myocardial infarction, atherogenesis, granulomatosis
with polyangitiis) [88–91], physiopathological conditions
(e.g., trauma) [92], or physiological states such as intense
effort [93, 94]. Only a few clear crucial observations are made
in the field of oncology with regard to theragnostics, progno-
sis, or patient follow-up [82, 83, 85, 95–97], but several pub-
lications converge to state the need for assaying cirmtDNA in
order to associate its level either with inflammation processes
[92, 98, 99] or the extracellular DNA TRAPs phenomena
[100] which recently appeared to have an identified role with
regard to tumorogenesis and metastasis [101, 102] (see
paragraph toward Sect. 3.4). Due to the multiple copy
characteristic of this DNA (many dozens of thousands of
copies per cell), it seems judicious to be interested in
cirmtDNA detection that appears to be an important
source of cirDNA. In addition, important mitochondrial
DNA somatic mutation level and important level of copy
number variation have been reported for a number of can-
cers [103–105] and could be analyzed via cirmtDNA. In
this context, we have initiated studies on cirDNA of mi-
tochondrial origin showing that cirmtDNA is present in
major amount in the blood (unpublished data). The deter-
mination of the mean values of cirmtDNA is currently
under study with samples from different cohorts, permit-
ting a tight statistical analysis. We have also performed
experiments using samples from xenografted mice reveal-
ing that tumor and non-tumor cirmtDNA concentrations
are elevated (unpublished data). Interestingly, we have
shown that human tumor cirmtDNA is more fragmented
than mouse non-tumor cirmtDNA (unpublished data). The
experiments employing clinical samples show a level of
integrity close to one in both cancer patients and healthy
subjects (unpublished data): This highlights the important
structural differences with nuclear cirDNA. It is already
possible to imagine this difference by the fact that the
mitochondrial DNA is a small DNA (16,000 bp), circular
and unprotected by histones, that which excludes the pos-
sibility of a nucleosomal structure unlike the cirDNA of
nuclear origin. Very few studies have considered the frag-
mentation of cirmtDNA: the experiments of filtration and
successive centrifugations using the plasma from healthy
individuals seem to indicate that cirmtDNA is composed
of associated and non-associated particles elements [87].
Ellinger et al. showed the integrity to be between 0.5 and
1.0 for healthy individuals and urological cancer patients
[83]. Another study showed the integrity index to be close
to one for healthy individuals and more elevated than in
carcinogenic agent exposed patients [85]. Same observa-
tion was made between healthy individuals and clear cell
renal carcinoma patients [106]. A work of Jiang et al.
showed that cirmtDNA was shorter than nuclear cirDNA
in cancer, cirrhotic, HBV-infected patients, and healthy
subjects [107]. This work did not show cirmtDNA struc-
tural differences between the healthy group and the affect-
ed patients [107]. These data imply the presence of a
Bstable^ structure, raising questions concerning the iden-
tification of these structures: are they the signature of the
presence of mitochondria in the blood? Are they especial-
ly stable lipoprotein complexes? A positive correlation
between the number of platelets and the cirmtDNA con-
centration has also been documented [87]. Nevertheless,
the reported data are actually insufficient and it is neces-
sary to make a systematic study of the structure of this
DNA employing well-established mouse models and large
cohorts of clinical samples.
Specific cellular cirDNA originsUnsuccessful attempts were
made in the past to decipher the cirDNA origin by determining
the sequence of cirDNA fragments [108]. However, Shendure
et al. were able to determine the cell type of origin by gener-
ating maps of genome-wide in vivo nucleosome occupancy by
using deep sequencing of plasma cell-free DNA [109].
Nucleosome spacing inferred from cirDNA in healthy indi-
viduals correlates most strongly with epigenetic features of
lymphoid and myeloid cells, consistent with hematopoietic
cell death as the normal source of cirDNA. Although this cell
origin is still dominant among the cirDNA fragment popula-
tion, this work showed as well malignant cell origin of cancer
patient-derived cirDNA. A recent work of Lehmann-Werman
et al. [110] involved a study of the specific tissue origins of
cirDNA in various affected diseased patients using cirDNA
methylation pattern analysis. They determined that cirDNA
was derived from pancreatic β cells in insulin-dependent dia-
betic patients, that cirDNA came from oligodendrocytes in
relapsing multiple sclerosis patients, and that after either
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cerebrovascular accident or heat attack, methylation analysis
of cirDNA from those patients revealed a neuronal/glial ori-
gin. Finally, in either pancreatitis or pancreas cancer patients,
they showed that it came from the exocrine pancreatic cells
[110].
cirDNA is not derived from CTCs Note, cirDNA does not
derive from circulating tumor cells (CTCs) that constitute an-
other biological source of the liquid biopsy approach. This
postulate resides on the fact that there is a discrepancy be-
tween the number of CTCs and the quantity of cirDNA in
the blood. As stated by Crowley et al. [33], Ba single diploid
human cell contains 6 pg of DNA and there is a median of
17 ng of DNA/mL of plasma in advanced-stage cancers;
therefore, if CTCs were the primary source of ctDNA it would
require over 2000 cells/mL of plasma. In reality, there are, on
average, less than 10 CTCs per 7.5 mL of blood.^ Our group
and others [67] have confirmed this observation.
Consequently, there are between 100 and 1000 times more
Genome equivalents in cirDNA as compared to CTCs.
2.2 Structures relevant to tumor-related cirDNA
2.2.1 The nucleosome
Apoptotic DNA cleavage produces a characteristic ladder pat-
tern of 180–200 bp or multiples thereof (oligonucleosomes) of
DNA fragmentation [108]. Apoptosis often leads to the deg-
radation of chromosomal DNA. DNA fragmentation results
from a caspase-activated DNase in the dying cells and by
lysosomal DNase II after the dying cells are phagocytosed
[111]. A nucleosome is composed of a histone octamer and
double-stranded DNA turned about this protein complex that
is stabilized by histone H1. Each nucleosome is linked to
another by double-stranded DNA, the linker DNA. The
DNA rolled around the histone octamer is 147 bp and the
linker DNA is 20–90 bp. The association of these fragments
assures a nucleosomal structural integrity that protects the
DNA from enzymatic degradation in the circulatory system
[112, 113]. The binding of the DNA around the protein com-
plex is made by electrostatic interaction, the DNA being neg-
atively charged and the protein positively charged. This frag-
mentation pattern could equally be the sign of a cell death
mechanism due to oncosis involving a cell death mechanism
known as ischemia [114]. It is characterized by mitochondrial
and nuclear swelling followed by cytoplasmic vacuolization
before cellular breakdown. Since 2001, Holdenrieder et al.,
using immunoenzymatic methods specific for nucleosomes,
have confirmed their presence in the circulatory system of
cancer patients with a lesser amount in healthy individuals
[112, 113, 115].
The characterization of a size comprising between 160 and
180 bp of cirDNA remained a postulate for a long time.
Nevertheless, more recent observations have shown that
cirDNA of tumor origin is more fragmented than cirDNA
deriving from healthy cells and with a sizemainly smaller than
145 bp [72, 73, 109].
2.2.2 Microvesicles of tumoral origin
In vivo microvesicles are particulates made of one or several
surrounding lipidic membranes encapsulating an aqueous
compartment that may contain cellular constituents or mole-
cules. An abnormally high number of microvesicles is secret-
ed and found in the blood of cancer patients [47, 116] with
many types of microvesicles being secreted by tumor cells
(Fig. 2): exosomes, apoptotic bodies, and other more hetero-
geneous microvesicles. All of these structures contain tumor
cell DNA. These microvesicles can possess a transforming
capacity [117, 118] and constitute a key structure of cirDNA.
Exosomes Exosomes are microvesicles measuring 30–
100 nm and secreted by most cells [119]. These microvesicles
have functional and biological properties, notably, the capac-
ity for lateral transfer of material. The exosomes are composed
of proteins and particular lipids as well as mRNA and
microRNA [120, 121]. Recently, it has been demonstrated that
exosomes also contain small amounts of DNA and exosomes
tumor-derived DNA has been characterized [122]: this seems
to exist in two main forms: one double-stranded form external
to the microvesicle is bound to the membrane and is of a large
size (>2.5 kbp). The other part of the double-stranded DNA,
less important, is in the interior of the vesicle and measures
100 bp to 2.5 kbp. Subsequent extraction of miRNA or
mRNA from exosome preparations from blood is considered
as a means of obtaining a high level of those circulating
nucleic acids toward developing a diagnostic panel of
mRNAs/microRNAs. However, it is not clear, as to whether
or not, there are more miRNAs in exosomes than in blood
[121] and that the methods used for their extraction eliminate
contamination by larger microvesicles.
Microparticles or ectosomes The microparticles (MPs), or
ectosomes, are membrane fragments measuring 200–
1000 nm in diameter [120]. They are released into extracellu-
lar compartments by most eukaryotic cells. Their formation is
the result of highly remodeled membranes accompanying the
process of the activation of/or cellular apoptosis leading to an
asymmetrical repartition of membrane phospholipids with ex-
ternalization of phosphatidylserine to the surface of the MPs.
They contain both DNA and RNA [123].
Apoptotic bodiesApoptosis is described as a cell deathmech-
anism characterized by its morphological changes, including
cell shrinkage, membrane blebbing, chromatin condensation,
and nuclear fragmentation. It is associated with fundamental
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cell phenomena such as cell survival as well as those that
control proliferation and differentiation. Defects in apoptotic
pathways are now thought to contribute to a number of human
diseases, ranging from neurodegenerative disorders to malig-
nancy. Apoptosis and the genes that control it have a profound
effect on the malignant phenotype [124].
Membrane blebbing leads to release from cells of apoptotic
bodies which are vesicles measuring between 1 and 5 μm
formed during the late phase of apoptosis and corresponding
to parts of a dying cell. Apoptosis induces cell cytoskeleton
breaks causing the membrane to bulge outward. These protu-
berances may separate from the cell, encapsulating part of the
cytoplasm, to become apoptotic bodies. These are then
engulfed by phagocytic cells and their components recycled.
They contain degraded DNA during apoptosis. The nucleic
acids contained in these apoptotic bodies will be protected
against the action of DNAses and RNAses [125].
2.2.3 Macromolecular structures
Virtosome or nucleic acid-lipoprotein complexes The
virtosome is a nucleic acid-lipoprotein entity discovered and
identified by P. Anker, M. Stroun, and P. Gahan. Their first
investigations revealed that non-dividing cells such as lym-
phocytes released DNA in their culture medium, confirming
earlier lymphocyte studies [52, 60, 126–129]. Subsequently,
Stroun and Anker showed that this released DNAwas newly
synthesized through 3H-thymidine labeling studies on lym-
phocytes and frog heart auricle pairs [60, 130] and that it
was associatedwith RNA [131]. Since both nucleic acids were
resistant to nuclease activity, it was considered that they were
protected by lipoprotein. Protein presence was determined by
RNAse activity affecting RNA only after treatment with pro-
teinase k [131–133] while the presence of lipids was deduced
from the complex’s behavior during density gradient centrifu-
gation [133], the effects of freezing and thawing on the com-
plex [132, 133], and the incorporation of radioactive phospho-
lipid precursors [132, 134]. Later studies employing radioac-
tive precursors demonstrated that the RNA, protein, and asso-
ciated phospholipids were also both newly synthesized and
synthesized at approximately the same time [131–133, 135].
This DNA/RNA-lipoprotein complex has been termed a
virtosome and was suggested to be an intercellular messenger
[51]. In vitro studies show the complex to be released in an
apparently energy-dependent step [132], only from living cells
[20, 132–134] and in a controlled manner [60, 130]. Labeling
experiments have shown that the components appear in the
cytoplasm at about 3 h after commencing labeling and that the
complex is released from cells 3–6 h later dependent upon the
origin of the cells studied, i.e., human, other mammalian, avi-
an, amphibian, and plant cells [52, 60, 126–130, 132–134,
136, 137]. The above studies (except for those in references
[132–135, 137]) were performed on the supernatants from the
culture media that had been centrifuged, initially, to remove
nuclei and cell debris followed by mitochondria and lyso-
somes prior to ultracentrifugation at speeds varying from
120,000 to 340,000g to yield the supernatant. Purification
was difficult since the complex did not pellet at these speeds,
did not pellet on centrifugation in a cesium chloride gradient,
and only partially migrated upward on a sucrose gradient
[132]. Thus, further purification was achieved by agarose gel
chromatography [133]. Studies of this fraction confirmed the
previous findings of the presence of newly synthesized DNA,
RNA protein, and phospholipids that separated in the same
fractions from the agarose gel column [133, 135] confirming
also the presence of a complex.
The complex isolated in this way from chick embryo fibro-
blasts also permitted the demonstration that the uptake of the
complex into fresh cells did not modify the isolated fraction
and that the complex remained the same both when released
from cells and when taken up by fresh cells [133]. This im-
plied that the complex did not have a standard limiting mem-
brane. This result was confirmed by a similar study on the
uptake by non-stimulated lymphocytes of the complex re-
leased from mouse tumor J774 cells [137].
Neutrophil extracellular DNA trapsNeutrophils represent a
significant portion of the tumor-associated inflammatory cell
infiltrate [138]. It has been shown that the tumor-associated
neutrophils (TANs) demonstrate pro-tumorigenic as well as
anti-tumorogenic properties related to their activation stage
[139–141]. NETosis by cell lysis is a cell death program of
neutrophils which occurs when neutrophils are activated by
pathogen agents or particular conditions: NETosis leads to
chromatin decondensation, lysis of cell and nuclear mem-
branes, and finally the release of neutrophil extracellular
DNA traps (NETs) [142]. NETs are composed of remodeled
extracellular DNA fibers and anti-microbial granules initially
present in the neutrophil [143]. This particular structure is
dedicated to both trap and kill pathogens (Fig. 7) [144]. It
has been shown that NETosis by cell lysis can be opposed to
the Bvital NETosis^, leading to release of DNA without the
cell lysing [145]. This may be activated under specific condi-
tions. The NETs, identified in 2004 [142], thus constitute, in
part, one of the origins of that which is called cirDNA.
Liberated under conditions of either infections or particular
pathophysiological states, these structures are equally interest-
ing from the functional point of view since it has been shown
that they possess biological and particular pathophysiological
effects notably in autoimmune pathologies, cancer, sepsis,
thrombotic illnesses, and in the inflammatory response [101,
146–150]. These situations are especially ones in which high
levels of cirDNA have been reported. It has also been shown
that after intense physical exercise, the neutrophils secrete
high levels of NETs, a situation in which high levels of
cirDNA have also been reported [151]. In this context, one
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cannot completely exclude that myocyte death is equally at the
origin of the release of cirDNA.
Eosinophil extracellular DNA traps As eosinophils are also
present in the tumor-associated inflammatory cell infiltrate
[152], it seems interesting to consider eosinophil extracellular
DNA traps (EETs) released from eosinophils under activation
[153]. Eosinophils stay viable after the release of EETs indi-
cating particular mechanisms of release. They contain only
mitochondrial DNA secreted in a catapult-like manner as op-
posed to neutrophil NETs that contain both nuclear and mito-
chondrial DNAs, indicating that this secretion is really an
active event and not a release following cell death [153,
154]. Inflammation has long been associated with the devel-
opment of cancer, in particular, with regard to the maintenance
of tissue homeostasis and repair [155]. So far, EETs were not
shown to be associated with cancer.
Circulating DNA linked with serum protein DNA, being a
very electrostatic molecule, is able to link with proteins pres-
ent in the circulatory system to form complexes [47, 48, 156,
157]. This was described to occur with some abundant pro-
teins such as either albumin or immunoglobulins and less
abundant serum proteins such as fibronectin and the C1q com-
plement component. Particular pathological situations
influencing the serum protein levels can cause a fluctuation
in the amount of cirDNA.
Circulating DNA linked to the cell surface Some DNA and
RNA are found at the surface of both leucocytes and erythro-
cytes in the blood [48, 49, 158]. In vitro, DNA fragments of
20 kbp are equally found at the cell surface [159]. This large
size may be explained by either a particular secretion/release
mechanism or by the fact that nucleases can have limited
access to this DNA. This DNA linked to the cell surface can
be either naked or associated with vesicular structures or
linked to macromolecules as previously described. At the cell
surface, there are some receptors capable of binding DNA, but
equally to allow it to enter cells [2]. It has been shown that the
nucleosomal structure was capable of crossing the cell mem-
brane [50, 125]. Some proteins, such as albumin, are able to
complex with cirDNA and favor its internalization into the
cell via endocytosis [125].
2.2.4 Size of cirDNA in cancer patients
Unclear distribution of cirDNA size in cancer patients
Knowing cirDNA size is of great interest for a better under-
standing of their structure(s) and origin(s) that can be related
to a particular tumor physiological/biological state, leading to
a higher diagnostic value. Unfortunately, the lack of harmoni-
zation of the methods used for pre-analytical procedures has
led to many controversies in the literature and has not permit-
ted the drawing of clear conclusions in this area [1, 160–163].
As has already been discussed, the most reported size corre-
sponding to mononucleosomes and oligonucleosomes [1,
108, 112] in the literature, has become the basic premise
concerning the structure of cirDNA for many years.
Nevertheless, other studies have described results that do not
agree with this concept. Many studies have shown the pres-
ence of large-sized fragments of many kbp [48, 108, 125, 164,
165]. The presence of fragments of this size could be the
signature of a mechanism of necrotic release. During necrosis,
the chromatin chain is degraded in an anarchic way and can
lead to fragments of >50 kbp. In contrast, we have shown by
using either a Q-PCR-based method or AFM that cirDNA in
cancer patients has a size mainly inferior to 145 bp [68, 69, 72,
166] (Fig. 8).
Circulating DNA of cancer patients is more fragmented
than that of healthy individuals Before developing a reliable
tool for the analysis of cirDNA from cancer patients, our group
Fig. 7 Neutrophil extracellular DNA traps. a Klebsiella pneumonia
bacterium (pink) snared in a neutrophil extracellular trap (green) in a
mouse lung. Credit: Papayannopoulos et al. (image by Volker
Brinkman and Abdul Hakkim). b Immunostaining double-labeling of
neutrophils releasing NETs isolated from tumor-bearing mice following
1 h activation with calcium ionophore (scale bar = 5 μm) (from Demers
and Wagner 224)
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has systematically analyzed the structure of tumor-derived
cirDNA using an animal model and cancer patient samples,
an approach not previously made [68, 73]. These studies have
shown for the first time that tumor-derived cirDNA is highly
fragmented and mainly composed of fragments <145 bp
(Fig. 9). In parallel, the analysis of tumor cirDNA showed it
to be more fragmented as compared to cirDNA from healthy
individuals. These observations have disagreed with those pre-
viously described in the literature, indicating that the prepon-
derant cirDNA size was 160–180 bp for cancer patients.
However, several years later, our work was confirmed by an
elegant study by Denis Lo’s group who, using a massively
parallel sequencing-basedmethod, showed the lower size mean
of cirDNA from hepatocellular carcinoma cancer patients [107]
(Fig. 10a). A recent work of Shendure et al. [109] remarkably
studied fragmentation patterns of cirDNA and revealed that
they constituted specific signatures of tissue origins of
cirDNA. Moreover, their acute deep sequencing and library
preparation methodology was designed to bypass the limits of
a conventional DNA library in order to recover damaged and
short double-stranded DNA fragments. They revealed that,
even if there is a dominant structure of 167 bp, a high propor-
tion of cirDNA fragments was below 167 bp [109] (Fig. 10b).
This strong result highlights the need to elucidate the structures
of cirDNA so as to improve their detection and analysis.
The observation that the sizes were mainly smaller than
145–160 bp calls into question apoptosis as the only origin
of cirDNA. The description of this size range indicated that
degradation, either enzymatically or by phagocytosis, oc-
curred in the circulatory compartment after DNA liberation
by either cell death or active secretion [47].
It seems that there are different cirDNA entities in the blood
of healthy and cancer subjects and that their respective dis-
crimination might be of valuable diagnostic value. In the light
of the prenatal fetal chromosomal aneuploidy test in pregnant
women, cirDNA size analysis could be used synergistically
with a counting approach to improve the accuracy of the de-
tection and cancer monitoring [68, 69, 107].
Size determination versus structure and origins The many
structures and mechanical origins evoked at the start of this
review showed that cirDNA is a complex entity. Sizing follow-
ing cirDNA extraction cannot fully account for characterizing
their structures because it results from numerous biological and
analytical variables. However, it is clear that knowledge on size
and fragmentation are keys in accurately detecting and quanti-
fying cirDNA, either total cirDNA or a fraction of cirDNA of
various origins (mitochondrial, nuclear, tumor or healthy cells,
tumor microenvironment cells, metastatic cells). In the light of
this observation, works on cell-free DNA collected from other
body constituents should rely on size specifics to their body
origin rather than on blood DNA data.
2.3 Subsequent fate of circulating DNA in the organism
The observations made on the structures and origins of cirDNA
are not just the result of the mechanisms described earlier
concerning the release of DNA into the circulatory system.
They are also conditioned by the subsequent fate of the
cirDNA in the organism, notably in the blood compartment.
Before considering the functional aspects of cirDNA, it is
necessary to consider its subsequent fate in the organism after
its release even though there are few publications on this sub-
ject. Such data have been determined mainly through either
plasmid DNA or genomic DNA extracted from cell tissues.
These DNAs were shown to be rapidly degraded by nucleases
present in the blood and rapidly metabolized/eliminated by the
liver and kidneys. Very little work has been focused on
cirDNA sensu stricto in its native state: among eight women
about to give birth, Lo et al. in 1999 determined that the mean
half-life for the elimination of cirDNA of fetal origin was
16.3 min [167]. They have shown elimination to be in two
Fig. 8 Vizualization of
circulating DNA by atomic force
microscopy. Circulating DNA
extracted from a metastatic
colorectal cancer patient plasma
sample vizualized by atomic force
microscopy (AFM) and compared
to SW620 genomic DNA ex-
tracted in the same conditions
than circulating DNA (adapted
from Mouliere et al. 69)
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Fig. 9 Malignant-derived circulatingDNA ismore fragmented than non-
malignant derived circulating DNA. SW620 xenografted mouse model: a
malignant (black bars) and non-malignant (hatched bars) cirDNA mean
concentrations are expressed as ng/ml of plasma; the bar height is the sum
of malignant and non-malignant cirDNA concentrations (estimated as the
total ctDNA concentration). CirDNAwas quantified by amplifying WT
KRAS exon 2 sequences of increasing size: 60, 100, 150, 200, 250, 350,
and 400 bp. b Fractional fragment size distribution of cirDNA amount
from malignant and non-malignant cirDNA in xenografted mice and
control cirDNA in non-xenografted mice. The cirDNA amount was arbi-
trarily estimated for the 60–100-, 100–150-, 150–400-, and >400-bp frag-
ment size ranges. Clinical samples: c comparison of the cirDNA fragment
size distribution of mutant (black bars) and WT (gray bars) cirDNA in
four plasma samples fromKRASmutant mCRC patients. Mutant cirDNA
was quantified by amplifying mutant KRAS exon 2 sequences of increas-
ing size from 60 to 390 bp. Non-mutant cirDNAwas quantified by am-
plifyingWTKRAS exon 2 sequences of increasing size from 60 to 390 bp
(adapted from Mouliere et al. [68, 72])
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phases: firstly, a slow elimination phase corresponding to a
distribution/elimination phase followed by a second, faster
phase corresponding to probably total elimination. In 2013,
using massively parallel sequencing in post-delivery women,
they confirmed a two-phase kinetics of fetal cirDNA. In this
study, they identified a first phase with a 1 h half-life time and
a second phase with a 13 h half-life time. They identified that
even if trans-renal excretion was involved in the process of
cirDNA elimination, it was not the major elimination mecha-
nism [168]. Diehl et al. have determined on only a single
colorectal cancer patient an elimination half-life time of
114min after surgery [169]. These data showing discrepancies
are currently insufficient and the determination of the subse-
quent fate of cirDNA in the organism is crucial for a better
understanding of its role in the organism and its turnover so as
to develop a tool for biomedical follow-up.
2.4 Discussion on the structure and origin of cirDNA
in respect to application in oncology
Due to the various cirDNA structures involved, and the subse-
quent various stability and fate, it is very difficult to determine
with full accuracy the respective proportion of each structural
entity. Such evidence would provide crucial information about
tumor biology, for instance, to distinguish the evolution be-
tween the primary tumor and metastasis. In addition, examin-
ing cirDNA structures respective proportions may shed a new
light on tumor dynamics, especially for following tumor pro-
gression, and so permit learning more about tumor aggressive-
ness in order to individually guide and tailor treatment for can-
cer patients (Fig. 11). On the other hand, specifically extracting
cirDNA based upon specific vesicular compartments or molec-
ular or intermolecular structures might be of great interest in
terms of its diagnostic power in some pathologies or in some
cancer phases such as metastasis (Fig. 11).
Hence, in addition to the work performed on detecting
specific sequences resulting from oncogenetic phenomena
such as either point mutations or aberrant methylation that
are mostly directed toward clinical applications such as
theragnostics, it appears that the quantitative determination
of malignant cells derived cirDNA as well as of non malignant
cells derived cirDNA is of great interest (Fig. 11). Scrutinizing
the structural heterogeneity of cancer patient, cirDNA analysis
could paradoxically, be a great opportunity to delineate diag-
nostic tools of higher performance.
3 Functional aspects
Two different striking discoveries with regard to the cirDNA
functional aspects were observed: the capacities as intercellu-
lar messenger and as genometastasis. This paragraph will also
describe the immunological properties of ccfDNA.
3.1 Capacity as intercellular messenger
3.1.1 Discovery and concept
The story began in the 1960s with the work of M. Stroun, P.
Anker, and P. Gahan in the context of an ideological war over
the Darwinian theory between the Russians and the West
[170–172]. Russian researchers were interested by a commen-
tary of Darwin concerning the nonsexual transmission of
Fig. 10 a Size distribution of malignant-derived circulating DNA.
Ninety hepatocellular carcinoma patient plasma samples were examined
by paired-endmassively parallel sequencing. Different malignant-derived
fractional concentrations were determined in HCC plasma samples (from
<2 to >8 %). While size distribution peaks at 166 bp, it shifted progres-
sively to the shorter size when malignant-derived cirDNA fraction in-
creases (from Jiang et al. [107]). b Size distribution of circulating DNA
in plasma sample from healthy individual as determined by next-
generation sequencing from a single-stranded library preparation. Short
fragments of 50–120 bp are considerably enriched as compared to con-
ventional library preparation (from Snyder et al. [109])
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characters through intervarietal vegetal graft experiments per-
formed by a number of English researchers [173, 174]. This
concept was also supported by experiments with blood transfu-
sion indicating the presence of a circulating entity carrying ge-
netic information and with a transforming capacity [175]. This
notion recalled that of Darwin’s Bgemmules^ structures circulat-
ing throughout the organism to reach the germinal cells where
they would permit the transfer of genetic information either
directly to the F1 generation or to the F2 generation with the
omission of expression in the F1 generation. This allowed
Darwin to explain how inherited features could Bjump^ a gen-
eration. The gemmules were defined as self-replicating struc-
tures that could also give rise directly to cells [173]. M. Stroun
repeated the Russian grafting experiments using eggplants in the
first approach and confirmed the transmission of acquired char-
acters (Fig. 12). He proposed that the nucleic acids are active
carriers of genetic information that circulate between the graft
and the reproductive cells of the stock that are responsible for the
transmission of genetic characters [16]. He also repeated blood
transfusion experiments from Guinea hens to white leghorn
chicken and observed alterations of the feather color in white
leghorn chickens [176]. From that time, the idea of cirDNAwas
born [16, 177]. M. Stroun and P. Anker repeated these experi-
ments on different plants and higher organisms and obtained
positive results. They demonstrated notably that on dipping the
cut shoots of a tomato plants in bacterial DNA, this foreign
DNA was found throughout the shoots attached to the host
DNA [59]. Subsequently, P. Gahan demonstrated that
Escherichia coliDNA carrying marker genes, which DNA does
not contain the DNA insertion system found in Agrobacterium
tumefaciens, could integrate into the plant host’s genome, mod-
ify it, and be expressed, showing a capacity for the horizontal
transfer of DNA [178].
M. Stroun, P. Anker, and P. Gahan also developed the con-
cept of transcession [171]: in repeating the experiments on
bacteria, plants, and higher organisms, they identified a com-
plex containing bacterial DNA and its DNA- and RNA-
dependent DNA polymerases capable of integrating the bacte-
ria genome into the host genome [19, 54, 179]. Upon the char-
acterization and identification of a similar complex in higher
organisms, these authors proposed the concept of virtosomes: a
lipoprotein complex containing DNA, RNA, and the DNA-
and RNA-dependent DNA polymerases [51]. This complex,
playing the role of intercellular messenger, is found in the su-
pernatant of culture medium and is actively secreted by cells in
a regulated manner [20, 60] (see part 2.2.3).
However, it is not obvious that only virtosomes may play an
intercellular messenger role. Given the apparent lack of a limit-
ing membrane and their size which is comparable to small lipo-
somes [180], it is likely that microvesicles might also be in-
volved in transferring genetic materials from one cell to another.
3.1.2 Penetration into the cell
The uptake of virtosomes released from one cell type by a
different cell type can result in a biological modification of
the recipient cells. Anker, Stroun, and Gahan demonstrated in
their works the transformation of NIH/3T3 cells on uptake of
released mutant k-ras from SW480 cells [181], an allogenic T–
B lymphocyte co-operation involving lymphocyte subsets from
human donors with different allotypes [182–184] and DNA
synthesis initiation in non-stimulated lymphocytes on uptake
of virtosomes released by J774 and P497 tumor cells [60].
Thus, the virtosome appears to be a novel cytoplasmic compo-
nent that may act as an intercellular messenger. While involve-
ment of proteolipidonucleic acid complexes appears to have
Fig. 11 CirDNA structure, origin, and function as regard to its analysis
toward clinical application. Physicochemical analysis of cirDNA, i.e.,
analysis of its sequence, its quantity, and its structure brings qualitative
and quantitative information useful for theragnostics, diagnostic,
prognosis, and follow-up in the context of cancer management care.
Analysis of the functions of cirDNA acting as an intercellular messenger,
an immune activator, and a mediator in metastatic progression provides
useful information for the follow-up of cancer patients by cirDNA
analysis
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been demonstrated, nothing precludes that microvesicles could
be able to show intercellular messenger function. A parallel
with DNA complexes synthetically formed to transfer short
DNA sequences such antisense or miRNAmolecules, or longer
DNA molecules such as plasmid DNA for regulating cell gene
expression either in vitro or in vivo [180] buttress this notion.
3.1.3 Role in the cooperation between B lymphocytes and T
lymphocytes in the humoral type of immune reaction
In 1975 and 1976, a series of experiments performed by M.
Stroun, P. Anker, and D. Jachertz revealed that T
lymphocytes, stimulated or not, released actively and sponta-
neously newly synthesized DNA, in a complex structure later
identified as a virtosome, into their culture medium [60, 185,
186].
In 1979 and 1980, they conducted in vitro experiments on
T cells and B cells from donors exposed to HSV [183, 187,
188]. Note that isolated T cells or B cells were not able to
produce an anti-HSV response. However, when isolating the
T cells’ released DNA following stimulation by HSV, and
adding it to the B cells’ culture medium for 3 days, anti-
HSV antibodies were synthesized with anti-allotypes of the
T cell donor by the B cells. Furthermore, in vivo experiments
have been conducted: nude mice were injected with DNA
released by T cells exposed to HSV or polio viruses [184,
188]. Five days after injection, those nude mice, never previ-
ously exposed to pathogens, produced specific anti-HSV or
Fig. 13 Representation of the main results showing the involvement of
cirDNA released by T cells in the humoral immune response in vivo.
Neutralizing activity of the serum of nude mice injected with DNA
released by human T cells previously exposed to UV inactivated HSV
or polio virus. Mice were injected with either 0.02 or 2 μg of human
DNA. Control mice remained uninjected. After 5 days, the mice were
killed and their serum was collected and frozen until tested. Numbers in
ordinate represent highest dilutions of serum still presenting neutralizing
activity (more than 3 units below virus control). Neutralization of HSV
(hatched area); neutralization of polio (solid area). Human released T-
DNA (α HSV) or T-DNA (α Polio) = DNA released by HSV or polio
virus-exposed human T-lymph (from Anker et al. [184])
Fig. 12 Demonstration of transmission of inherited characters by
hybridization in eggplants. Heterografts between S. melongena variety
Long violet (mentor plant) and the variety White round (pupil plant)
(from Stroun [16])
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anti-polio antibodies with human characteristics (Fig. 13).
Those observations seem to indicate a genetic transfer of in-
formation between T cells and B cells: T cell released DNA
could act as an intercellular messenger carrying the necessary
information for B cells to code the corresponding antibody.
3.2 Genometastasis
Among the physiological roles of cirDNA, the most obvious
that one can imagine is the capacity of Btransfection,^ a theme
that excites much interest among researchers. In 1965,
Bendich et al. published in Science BCirculating DNA as a
possible factor in oncogenesis^ [189]. They demonstrated that
tumor DNA injected into the mouse circulatory system was
the origin of tumor development and proposed the hypothesis
that DNA penetrated into healthy cells to render them tumor-
ous. This observation has since been extensively confirmed
and led to the concept of genometastasis [181, 190–192].
3.2.1 Discovery and concept
The genometastasis hypothesis is as follows: cirDNA released
by tumor cells is capable of transfecting healthy cells at a
distance from the primary tumor and leading to the formation
of metastases [192].
P. Anker and his collaborators were the first to demonstrate
the transfecting and transforming capacities of this extracellu-
lar DNA found in the culture medium of SW480 tumor cells
on NIH/3T3 mouse fibroblasts [181]. After exposure to the
SW480 culture medium, the NIH/3T3 cells not only became
tumorous, but in addition, carried the KRAS mutation present
in the SW480 cell line. In 2010, Garcia Olmo et al. observed
the same event with plasma obtained from a colorectal cancer
mutantKRAS carrier patient [190]. After adding this plasma to
the culture medium, the NIH/3T3 cells became tumoral and
carriers of the human KRAS mutation. Moreover, after the
injection of these transformed NIH/3T3 cells into NOD-
SCID mice, tumors containing the specific human KRAS mu-
tation were developed (Fig. 14).
3.2.2 Hypothetical mechanisms
Many structures carrying cirDNA can be involved in this
genometastasis: it has been shown that apoptotic bodies can
be responsible for this transformation at a distance, as can both
microsomes and exosomes [193]. The complexing of cirDNA
with proteins present in the circulatory system equally favors its
cellular internalization. In addition, it has been shown that nu-
cleosomes have the capacity to directly cross plasma mem-
branes and to penetrate into the nucleus [194]. Virtosome could
equally be involved in this phenomenon in penetrating other
cells and modifying their genetic program [193]. Another re-
cent study by Mittra et al. [195] clearly showed that there was
an integration of cirDNA in host cells: after addition of human
derived cirDNA to murine cells culture, they revealed the cel-
lular entry, the nuclear uptake of human ccfDNA into murine
cells and the colocalization of human ccfDNA and murine ge-
nomic DNA on karyotypes from metaphase spreads [195].
Furthermore, Mittra et al. showed that this uptake and genomic
integration was responsible for apoptosis activation and DNA
damage into host cells [196] (Fig. 15). Remarkably, those ef-
fects were greater with cirDNA from cancer patients as com-
pared to that from healthy donors.
Fig. 14 Schematic representation
of the observing genometastasis.
Plasma from colon cancer
patients, in which a KRAS
mutation had been detected, had
been added to cultures of NIH/
3T3 cells. Human KRAS DNA
was detected soon afterward in
these cells. Treated cells were
injected, subsequently, into NOD-
SCID mice and macroscopic tu-
mors were generated. After sacri-
fice, human mutant KRAS se-
quences were detected in primary
tumors, plasma, lungs, and livers
of injected animals (from Garcia
Olmo et al. [190])
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While those biological effects have been demonstrated, the
mechanisms of DNA integration into the host genome need to be
elucidated. Note that in 1969, Gahan, Anker, and Stroun reported
that when roots of Vicia faba were treated with heterologous
DNA (salmon sperm), DNA damage occurred in the host cells
[197]. This appeared to be due to the heterologous DNA break-
down by DNAse on entry into the roots so increasing the nucle-
otide concentration in the cells and leading to chromosome dam-
age. This did not occur with the homologousV. fabaDNA [198].
Furthermore, membrane vesicles double-stranded DNA natu-
rally found in the subcellular particulate fraction of some bacteria
(such as Ruminococcus or Mycobacterium) are able of transfor-
mation [199]. It appears that membrane-associated heritable
transformation plays a role in lateral gene transfer in complex
microbial ecosystems.Acquisition of genetic information through
horizontal gene transfer (HGT) is an important evolutionary pro-
cess by which microorganisms gain novel phenotypic character-
istics [200]. Several works support the idea that the genomes of
certain eukaryotes have been exposed to exogenous DNA more
frequently and continuously than previously thought [201].
In fact, horizontal gene transfer has happened between dif-
ferent kingdoms of life throughout the history of life on the
planet [202, 203]. It seems that the genome of just about every
modern species is something of a mosaic constructed with
genes borrowed from many different forms of life. We must
now acknowledge that, even among the most complex organ-
isms, vertical is not the only direction in which genes travel
[204]. Thus, HGT was prematurely revealed by early works
from Anker and Stroun in plants or eukaryotic cells in mice in
the way of the cirDNA discovery.
HGT is defined as the transfer of genes between organisms
in a fashion other than is found through traditional reproduc-
tion. Thus, while in the case of the initial experiments defining
genometastasis, the movement of the human mutant KRAS
cirDNA to murine cells can be considered as a horizontal
DNA transfer, the movement of self DNAwithin an organism
cannot be also considered.We suggest also that other situations,
whereby the cirDNA can enter cells and modify the biology of
the recipient cells in the same organism, cannot be defined as
HGT since the DNA is present as fragments of genes and not
whole genes. We would suggest that this process is more cor-
rectly termed as intra-organism genetic transcession (IGT).
The term transcession was initially derived to describe the
release of DNA by bacteria and its biological activity in plants
and animal tissues [205, 206].
3.3 Pro-inflammatory and immunological effects
3.3.1 Circulating DNA: a DAMP
Immunostimulatory characteristics of circulating DNA
DNA constitutes a macromolecule with immunostimulating
properties. The particular DNA double-helix structure, the
particular motifs of certain sequences and the molecular inter-
actions are three factors at the origin of the stimulation of the
immune response [207]. In effect, the exposure of cells of the
innate immune system to double-stranded DNA notably pro-
vokes the activation of the genes regulating interferon secre-
tion (INF) and other pro-inflammatory molecules. This stim-
ulation is at the origin of a strong inflammatory response
Fig. 15 Induction of double-strand DNA breaks and apoptosis by
cirDNA into NIH/3T3 cells. Induction of γ H2AX and active caspase-3
by fragmented circulating DNA (DNAfs) and circulating chromatin (Cfs)
derived from healthy volunteers (red bars) and cancer patients (gray
bars). In vitro analysis of γ H2AX and active caspase-3: NIH/3T3 cells
(10 × 104) were treated with DNAfs and Cfs (5 ng DNA each) for 6 h for
detection of γ-H2AX (left) and for 24 h for detection of active caspase-3
(right) by immunofluorescence. For γ-H2AX (left-hand panel), 300 nu-
clei were counted and the percentage of nuclei showing positive foci were
calculated and analyzed by chi-squared test. For active caspase-3 (right-
hand panel), 200 cells were counted and the percentage of cells showing
positive fluorescent signals were calculated and analyzed by chi-squared
test (from Mittra et al. [195]) (color figure online)
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mediated by the secretion of cytokines. DNA alone can acti-
vate the immune system, but this can also occur on its
complexing with other molecules [47, 207]. The abundant
presence of nucleic acid receptors in the cell confirms its im-
portant role in the innate immune system [208]. In the normal
state, it appears that the presence of DNAse in the circulatory
system permits DNA degradation, blocking this stimulation. It
has been shown that DNAse-deficient mice were particularly
sensitive to the development of autoimmune pathologies [209,
210]. Twenty percent of LED patients are deficient in DNAse
[211, 212].
Mechanisms of circulating DNA recognition Some cirDNA
recognition mechanisms have been demonstrated: one Toll-
like receptor (TLR) 3-7-8-9 pathway and one independent
TLR less important pathway that will not be detailed here
[209]. The TLRs are implicated in the innate immune re-
sponse and are present in dendritic cells and macrophages. It
involves the receptors being implicated in recognizing par-
ticular molecular motifs derived from pathogenic organisms:
the pathogen-associated motif pattern (PAMP) [213]. The
binding ligand-TLR provokes the activation of transcription
factors NFkB/AP1 that regulate the induced expression of
inflammatory cytokines such as tumor necrosis factor
(TNFα) or interleukin-1 (IL-1) or interleukin-6 (IL-6), and
co-stimulating molecules CD80 and CD86. The molecular
ligands can equally be of endogenous origin: fibrinogen,
heat shock proteins, high-mobility group protein B1
(HMGB1), and self cirDNA. These endogenous ligands are
called damage-associated motif pattern (DAMP) [209, 213,
214].
In these particular pathological conditions, cirDNA is not
degraded by the nucleases and thus can complex with other
proteins and reach the cellular TLR implicated in nucleic acid
recognition: TLRs 3, 7, 8, and 9. Among these receptors,
TLR9, present in intracellular endosomal vesicles, but equally
at the extracellular surface of polynuclear neutrophils (PNNs),
is implicated in the recognition of small-sized oligonucleotides
(20–30 nt) containing demethylated CpG motifs. The binding
of these ligands by TLR9 is at the origin of an innate immune
response characterized by an inflammation mediated by the
secretion of cytokines by the action of NF-kB (Fig. 16) [215].
Fig. 16 Interaction between DNA
and TLR9. Class III
phosphatidylinositol 3-kinase
(PI3K) facilitates the internalization
of CpG oligodeoxynucleotides
(ODNs) into endosomal vesicles
that contain Toll-like receptor 9
(TLR9). The interaction between
CpG DNA and TLR9 transduces
an intracytoplasmic activation sig-
nal. The signal initiates with the re-
cruitment of myeloid differentiation
primary response gene 88
(MYD88) to the Toll–interleukin-1
receptor (TIR) domain of TLR9,
followed by activation of the
IRAK–TRAF6 complex. This
leads to the activation of both the
mitogen-activated protein kinase
(MAPK: JNK1/2 and p38) and in-
hibitor of nuclear factor-kB (NF-
kB) kinase (IKK) complexes, cul-
minating in the upregulation of
transcription factors, including NF-
kB and activating protein 1 (AP1).
ATF1, activating transcription fac-
tor 1; IRAK, IL-1 receptor-
activated kinase; JNKK1, c-JUN
N-terminal kinase (JNK) kinase 1;
NIK, NF-kB-inducing kinase;
TRAF6, tumor-necrosis factor
receptor-associated factor 6 (from
Klinman [215])
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3.3.2 The particular case of circulating mitochondrial DNA
Due to the bacterial origin of mitochondria [216], circulating
mitochondrial DNA presents a particular structure able to ac-
tivate the immune system because of the similar structure
between mitochondrial and bacterial DNA [98]. In effect, mi-
tochondrial DNA presents the same circular structure as bac-
terial DNA, is protein-free, and possesses a number of
demethylated CpG islands. Its release under certain patholog-
ical conditions can lead to the activation of the immune system
and an unleashing of an inflammatory response. Some works
have shown that the mitochondrial DNA activates the polynu-
clear neutrophils on specific binding to TLR9 [217] (Fig. 17).
This interaction is at the origin of the inflammatory response
via p38 [92].
3.3.3 Clinical manifestations
The first evidence of the immunostimulatory properties of
cirDNA dates from the 1960s and the studies of SLE [27]. One
characteristic of such patients is the presence of anti-cirDNA
antibodies. cirDNA is, thus, characterized as an antigen and the
immune complex anti-cirDNA antibodies—cirDNA attaches to
the basal membranes to provoke an inflammatory reaction [218].
Subsequently, cirDNA analysis in states of inflammation and
autoimmune pathologies constitutes a vast fundamental and clin-
ical research field [32]. A relationship between increased
cirDNA of fetal origin in women with a complicated pregnancy
and some cases of either spontaneous abortion or premature
births has been demonstrated [219]. The very high concentration
of fetal cirDNA found with some complications such as pre-
eclampsia can be explained by an abnormal level of cell death
of fetal cells [220, 221]. The fetal DNA being hypomethylated
has been shown to bind to TLR9 receptors of the mother’s im-
mune cells so unleashing an inflammatory response leading to
the situations of either premature birth or spontaneous abortion
[219].
3.4 Other mechanisms involved in tumor progression
mediated by circulating DNA
The identification in 2004 of new structures such as the
Bneutrophil extracellular DNA traps^ (NETS) [142] and later
the Beosinophil extracellular DNA traps^ (EETS) [153], and
their mechanism of liberation by ETosis, opens a particularly
appealing new field of investigation. These extracellular DNA
structures are secreted by Bpolynuclear^ cells following their
stimulation by either pathogenic agents or under certain phys-
iopathological conditions such as inflammation [222]. The in-
volvement of these structures in processes such as
hypercoagulation or autoimmune pathologies have been de-
scribed and, interestingly, high concentrations of cirDNA have
been well-documented for patients presenting with pathophys-
iological problems [223] (see Sect. 2.2.3). The NETs could be
implicated in tumor progression [224]. It has already been de-
scribed that high levels of circulating polynuclear neutrophils
are positively correlated with a reduction of the global survival
rate because they may be responsible for metastatic progression
[225]. Thus, it has been shown that the polynuclear neutrophils
intervene as Bbridges^ between the circulating tumor cells and
the hepatic and lung surface epithelia, favouring their adhesion
to the surface of these organs and in fine metastatic dissemina-
tion. Equally, they could secrete factors aiding the adhesion of
the circulating tumor cells to endothelial surfaces [226]. Recent
work has shown links between NETs, circulating tumor cells
and metastatic progression using a mouse lung cancer model
Fig. 17 Involvement of mitochondrial cirDNA in the inflammatory
process. Similar to the release of bacterial DNA following sepsis, the
mitochondrial DNA released by severe trauma can also act through the
Toll-like receptor 9 (TLR9) to activate neutrophils by activating p38
MAP kinase (MAPK). DAMPs damage-associated molecular patterns,
PAMPs pathogen-associated molecular patterns. Adapted from © 2010
Nature Publishing Group Calfee, C. S. & Matthay, M. A. Clinical immu-
nology: culprits with evolutionary ties. Nature 464, 41–42 (2010). All
rights reserved
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[101]. In this study, the authors demonstrate that the NETs
capture circulating tumor cells in the blood, aiding their adhe-
sion to hepatic endothelia and hence metastatic dissemination.
This observation shows the Banchorage^ capacity of the NETs
and their possible roles inmigration and adhesion. Interestingly,
it has been shown that the EETs contain only mitochondrial
DNA, the absence of nuclear DNA indicating an active mito-
chondrial DNA release in certain conditions [154].
3.5 A potential therapeutic target
The description of the biological and the pathophysiological
effects described in this review raises the obvious question of
considering cirDNA as a therapeutic target. This concerns two
major principles namely, the implication of cirDNA in tumor
progression via genometastasis and its role as a danger signal
activating the immune system. Some researchers have consid-
ered that treatments byDNAse/RNAse, via a general pathway,
permitting the destruction of these cirDNAs so as to reduce
tumor progression [227]. Various cancer cell lines have been
xenografted onto mice to test the efficacy of DNase treatment.
For instance, experiments have been performed in vivo on
lung tumor-bearing mice and have shown that the daily ad-
ministration of DNase was at the origin of the reduction of
metastatic progression [228, 229] (Fig. 18). Some preliminary
experiments performed in vivo on rats that have developed
tumors following injection of extracellular DNA derived from
the culture medium of SW480 colorectal carcinoma cells by
the phenomenon of genometastasis have shown that treatment
with DNase was responsible for the reduction of tumor pro-
gression [230]. DNase or neuro-elastase inhibitor treatment
should also be effective in the destruction of NETs implicated
in metastatic spreading by sequestration of CTCs [101].
Another group was interested in the general administration
of cationic polymers that permitted a complexing with
cirDNA by electrostatic interactions [231].
Their in vitro and in vivo results have shown that certain
polymer formulations permit inhibition of the inflammatory re-
action while maintaining a normal activity of the immune sys-
tem with respect to other danger signals such as viruses [232].
These original studies shed a light upon an aspect, currently
little documented, on cirDNA and could open up interesting
areas in the field of cancer, inflammatory, and autoimmune
therapeutics.
4 Circulating DNA: from controversy
to breakthrough in oncology
The hypothesis of cirDNA originated from basic research ob-
servations made from plant graft hybrid experiments per-
formed by Maurice Stroun following on from the work of
the Russian biologists of the 1950s. He made this hypothesis
to explain why, in his graft experiments made on eggplants,
some characteristics of the mentor plant appeared in the
grafted pupil plant. The concept of cirDNA was, of course,
not very easy to impose and the fact that it originated from not
always controlled experiments did not help. Maurice Stroun’s
data, once published in 1962 [16, 176], were hardly believed,
and, as a consequence, he lost his funding from the Swiss
National Fund for Scientific Research [233]; he could not
even have access to the criticisms of the experts. Professor
Chodat, Director of the team where he worked, in particular
the works in collaboration with Sidransky, backed him but,
consequently lost the possibility to become Rector of the
University of Geneva [233].
The graft hybrid experiments were considered to be a dan-
ger for the university and even for the reputation of
Switzerland. Following months-long struggles with the uni-
versity, Maurice Stroun resigned his post and left Geneva
where he had no opportunity to work. After a few years in
Belgium and in Israel, he came back in 1970 to Geneva where
he worked with Philippe Anker. Severe criticisms occurred
when they published that living cells, frog auricles, and human
lymphocytes spontaneously released DNA [170, 187]. The
difficulties and pressures again returned from both the univer-
sity and the Swiss National Fund for Scientific Research. In
spite of the publication by J.C. Rogers in 1972 [52] of a report
showing that stimulated lymphocytes released newly synthe-
sized DNA, the Swiss National Fund refused to grant a re-
search project because some experts postulated that either the
discoveredmolecule was not DNA or that the observation was
due to contaminating bacteria. Grant applications from Drs.
Stroun and Anker were refused on each occasion, and some
critics were straightforward without any explanation using
comments such as Bmiles away from real Science.^
Following several refusals and even falsification of the expert
Fig. 18 The metastasis suppression effect of RNase A or DNase I on
Lewis lung carcinoma (LLC) metastatic mouse model. Typical
histotopograms of lung lobes in the control and experimental groups
treated with RNase A and DNase I. Hematoxylin and eosin staining.
Arrows indicate large metastases. Bar corresponds to 5 mm (from
Patutina et al. [228])
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comments of the reviewers on a grant application to make
them negative, Maurice Stroun and Philippe Anker undertook
a libel suit for defamation in 1985, but the judge of the
Department of Justice of the canton of Bern abandoned the
affair. While in 1987 and 1989, Maurice Stroun and Philippe
Anker had reached some international fame with the discov-
ery of circulating nucleic acids in the plasma of cancer patients
[22, 46], had published in top journals, in particular works in
collaboration with Sidransky, and had been invited all over the
world, grant applications continued to be obstructed. Despite,
finally, some funding from the Swiss League against Cancer,
more money was needed for performing further investiga-
tions. Without help from some private donors, they would
have had to close their laboratory.
The fields of science are full of crucial discoveries that
were not taken into consideration at time of their reporting.
Rarely, the discovery of a class of biological compounds was
so retarded in their applications as was cirDNA. Since their
discovery in 1948 it took 57 years before starting to clinically
evaluating their potential. In the light of the various clinical
applications, especially in oncology, now in progress such as
diagnosis, prognosis, therapy monitoring, or patient follow-
up, the forces impeding full recognition of this discovery
should be analyzed by the scientific community so as to over-
come any future, similar difficulty.
The early obstinate position of first Drs. Stroun and Anker
illustrates that human resilience is sometimes a requisite for an
emerging discovery. However, sometimes this resilience may
be confronted by a scientific community that is inclined to
maintain existing paradigms or dogmas. It appears that late
recognition of P. Anker, M. Stroun, and P. Gahan was damag-
ing to cancer science and patients. It is certain that cirDNA is a
breakthrough discovery that would impact standard manage-
ment care of cancer patients as well as other clinical disorders
[35]. For instance, works from the groups of L. Diaz [67, 169],
N. Rosenfeld [75, 234], A. Bardelli [235], AR Thierry [70,
74], or N. Turner [236] recently demonstrated the clinical
validation and utility of cirDNA in oncology.
Following the first demonstration of the capacity of detect-
ing RASmutations from cirDNA analysis by Vasioukhin et al.
[23] and Sorenson et al. [24], in collaboration with P. Anker
andM. Stroun, in acute myeloplastic syndrome and pancreatic
cancer, respectively, Diehl et al. presented the first clinical
evaluation of the detection of molecular alterations from
cirDNA [26]. Thierry et al. reported in 2014 the first clinical
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examining the KRAS/BRAF mutations in colorectal cancer
patients [70]. CirDNAwas shown to help in dynamically es-
timating the tumor burden and to follow-up patients during
management care (Fig. 19) [169, 234, 237]. Non-invasive
analysis of acquired resistance to cancer therapy by analyzing
plasma DNAwas later demonstrated in breast and colorectal
patients [75, 235, 238]. Lastly, Garcia-Murillas et al. [236]
showed that quantitative mutation tracking in serial samples
increased sensitivity for the prediction of relapse in early
breast cancer suggesting an application of cirDNA in the sur-
veillance of the recurrence and detection of the minimal resid-
ual disease. Thus, qualitative as well as the quantitative anal-
ysis of cirDNA in various malignancies are now intensively
investigated and critical data are expected to be exponen-
tially reported toward probable changes in the cancer
clinical practice (see review [33, 34]). In addition to the
predictive information and perhaps screening capacities
as determined from tumor tissue analysis, tracking resis-
tance, surveillance of the recurrence, detection of the
minimal residual disease or screening are solely enabled
by analyzing cirDNA facilitating longitudinal personal-
ized medicine for cancer patients (Fig. 19). A most recent
evidence for the development of cirDNA is the positive
approval emitted by the Committee for Medicinal
Products for Human Use (CHMP) of the European
Medicines Agency (EMA) for Iressa® (gefitinib). This
allows doctors to identify suitable lung cancer patients
by testing for EGFR mutations that are predictive of ther-
apeutic response with this drug in the absence of a tumor
sample. As the clinical utility of this application appears
straightforward, this would pave the way to a larger uti-
lization of cirDNA in oncology practice. Thus, if predic-
tive information (companion test) and monitoring drug
resistance are the two first approved clinical applications,
it is highly probable that the future applications will be
on monitoring treatment therapy, prognosis, minimal re-
sidual disease, surveillance of the recurrence/noninvasive
follow-up of the disease, or even a screening test
(Fig. 19).
This field benefited from development of technolo-
gies such as Q-PCR-based methods (e.g., allele-specific
Q-PCR, digital Q-PCR, BEAMing), sequencing-based
methods (e.g., next-generation sequencing, Cap-Seq,
TamSeq), or chromatographic-based methods such as
Fig. 20 Timeline of the main important discoveries about circulating DNA applications and functions
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advanced mass spectrometry [34]. Their further develop-
ment or the emergence of new, advanced technologies
would allow for highly specific analysis of cirDNA. In
association with the better understanding of the structur-
al properties of cirDNA, both biological and functional
(Figs. 11 and 20), with a focus on the tumor and me-
tastasis processes, such future progress would warrant
wide cirDNA clinical applications in oncology.
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